PAX5 and hematopoietic and lymphoid cell neoplasm: Accordingly, the methylation profile of the PAX5 promoter region has been proposed as a potential tool with clinical applicability for prognostics and diagnostics in the classification of non-hematological cancer subtypes [74,105,106,107].